A Novel Single-Stranded RNA-Based Adjuvant Improves the Immunogenicity of the SARS-CoV-2 Recombinant Protein Vaccine.
Liu D, An C, Bai Y, Li K, Liu J, Wang Q, He Q, Song Z, Zhang J, Song L, Cui B, Mao Q, Jiang W, Liang Z.
Liu D, et al. Among authors: an c.
Viruses. 2022 Aug 24;14(9):1854. doi: 10.3390/v14091854.
Viruses. 2022.
PMID: 36146661
Free PMC article.
The research and development (R&D) of novel adjuvants is an effective measure for improving the immunogenicity of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant protein vaccine. ...L2, with adjuvant compatibility with RBD, elevated the ant …
The research and development (R&D) of novel adjuvants is an effective measure for improving the immunogenicity of the severe acut …